Upcoming events – Vertex awaits triplet data and GBT seeks approval for approval
Vertex is due the first pivotal data on its cystic fibrosis triplets, while Global Blood Therapeutics will soon find out whether it can take a shortcut on voxelotor’s…
Volatility returns for big biopharma
The downs are more pronounced than the ups as the macroeconomic climate turns against big pharma and biotech.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.